RxDoctor Payments Data

Olga Kaczaj, MD

Internal Medicine · Vineland, NJNPI 1518055755

Payments from drug & device makers

$8,382in general payments, 2019–2025

Across 571 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$760
  • Pfizer$527
  • Lilly USA, LLC$480
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,382 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$218,473
Medicare patients
354
Services billed
2,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$68,137
MounjaroTirzepatide20$36,026
XareltoRivaroxaban25$35,879
EliquisApixaban41$31,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$29,305
JardianceEmpagliflozin25$26,751
JanumetSitagliptin Phos/Metformin Hcl16$25,154
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$14,611
Tresiba Flextouch U-100Insulin Degludec14$8,929
Atorvastatin Calcium696$8,693
Icosapent Ethyl11$7,927
Levothyroxine Sodium632$7,700
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,005
Metoprolol Succinate359$5,547
Rosuvastatin Calcium382$5,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,107$68,13745 claims
Lilly USA, LLCMounjaro$480$36,02620 claims
Johnson & JohnsonXarelto$13$35,87925 claims
PfizerEliquis$527$31,01641 claims
GSKTrelegy Ellipta$276$29,30522 claims
Boehringer IngelheimJardiance$208$26,75125 claims
MerckJanumet$25$25,15416 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,210$17,00325 claims
AbbVieSynthroid$1,670$5,28864 claims
Almatica Pharma LLCSertraline Hcl$47$3,649132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →